title: Combined tamoxifen-lynestrenol treatment in benign breast disease.
abstract: In order to avoid secondary induction of estrogens caused by tamoxifen treatment, tamoxifen was associated with the progestative lynestrenol in 48 menstrual women with benign breast disease (adenoma or fibroadenoma, cystic, simple or complex dysplasia). In one variant tamoxifen dosage was 20 mg (2 tablets) daily taken orally from day 5 to day 25 of the menstrual cycle, associated with 10 mg (2 tablets) of lynestrenol daily, only during the last 15 days. In another variant the above mentioned drugs were given concomitantly from day 10 to 15 of the cycle (according to cycle length) for 10 days. The average duration of the treatment was 4 cycles. The results are analysed according to surface percentage reduction of the main and associated lesions within the same case. In all cases of simple dysplasia, in 78% of the cases with complex dysplasia and in 54% of the adenomas, the lesions decreased to less than half their initial size, and in some instances the lesions disappeared altogether and the breasts became normally soft. Breast pain was improved or disappeared altogether in 96% of the cases. Despite its positive results the associated treatment used should be applied only in certain cases, especially those diagnozed as complex dysplasia and only in those medical units that have adequate diagnosis and treatment follow-up facilities.
mesh_terms: D000232:Adenofibroma / Q000188:drug therapy*; D000236:Adenoma / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005348:Fibrocystic Breast Disease / Q000188:drug therapy*; D006801:Humans; D008234:Lynestrenol / Q000627:therapeutic use*; D008597:Menstrual Cycle / Q000187:drug effects; D008875:Middle Aged; D013629:Tamoxifen / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D013629:Tamoxifen; D008234:Lynestrenol